- Home
- NUVB vs BXC Comparison
NUVB vs BXC Comparison
Compare NUVB & BXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- BXC
- Stock Information
- Founded
- NUVB 2018
- BXC 2004
- Country
- NUVB United States
- BXC United States
- Employees
- NUVB N/A
- BXC N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- BXC Wholesale Distributors
- Sector
- NUVB Health Care
- BXC Consumer Discretionary
- Exchange
- NUVB Nasdaq
- BXC Nasdaq
- Market Cap
- NUVB 774.1M
- BXC 869.2M
- IPO Year
- NUVB N/A
- BXC 2004
- Fundamental
- Price
- NUVB $2.21
- BXC $82.41
- Analyst Decision
- NUVB Strong Buy
- BXC Strong Buy
- Analyst Count
- NUVB 6
- BXC 4
- Target Price
- NUVB $7.67
- BXC $127.75
- AVG Volume (30 Days)
- NUVB 1.7M
- BXC 70.3K
- Earning Date
- NUVB 03-03-2025
- BXC 02-18-2025
- Dividend Yield
- NUVB N/A
- BXC N/A
- EPS Growth
- NUVB N/A
- BXC 14.84
- EPS
- NUVB N/A
- BXC 6.19
- Revenue
- NUVB $2,162,000.00
- BXC $2,952,532,000.00
- Revenue This Year
- NUVB N/A
- BXC N/A
- Revenue Next Year
- NUVB $374.06
- BXC $4.41
- P/E Ratio
- NUVB N/A
- BXC $13.33
- Revenue Growth
- NUVB N/A
- BXC N/A
- 52 Week Low
- NUVB $1.67
- BXC $82.23
- 52 Week High
- NUVB $4.16
- BXC $134.79
- Technical
- Relative Strength Index (RSI)
- NUVB 37.58
- BXC 22.63
- Support Level
- NUVB $2.16
- BXC $86.21
- Resistance Level
- NUVB $2.38
- BXC $103.10
- Average True Range (ATR)
- NUVB 0.12
- BXC 3.66
- MACD
- NUVB 0.00
- BXC -1.99
- Stochastic Oscillator
- NUVB 16.13
- BXC 0.69
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About BXC Bluelinx Holdings Inc.
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.